Početna › Multipli mijelom › Massachusetts
Kliničke studije za Multipli mijelom u državi Massachusetts
44 studija za Multipli mijelom traži sudionike na lokacijama u državi Massachusetts.
Gradovi u državi Massachusetts
Službeni tekst studije (engleski)
A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)
- Research Site, Boston
- Research Site, Boston
U tijeku regrutacijaFaza 3
Od 18 godina i više · Oba spola · Ažurirano 29. ruj 2026. · NCT07391657A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
- Tufts Medical Center, Boston
U tijeku regrutacijaFaza 3
Od 18 godina i više · Oba spola · Ažurirano 25. ruj 2026. · NCT07518186A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
- Dana Farber Cancer Institute, Boston
- Boston University Medical Center, Boston
U tijeku regrutacijaFaza 3
Od 18 godina i više · Oba spola · Ažurirano 25. ruj 2026. · NCT07258511A Study to Compare Linvoseltamab and Daratumumab Treatment in High-Risk Smoldering Multiple Myeloma (HR-SMM)
- Dana Farber / Harvard Cancer Center, Boston
U tijeku regrutacijaFaza 3
Od 18 godina i više · Oba spola · Ažurirano 25. ruj 2026. · NCT07393282A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel
- Dana Farber Cancer Institute, Boston
- Beth Israel Deaconess Medical Center, Boston
- Massachusetts General Hospital, Boston
U tijeku regrutacijaFaza 4
Od 18 godina i više · Oba spola · Ažurirano 25. ruj 2026. · NCT05201781A Study of mRNA-2808 in Participants With Relapsed or Refractory Multiple Myeloma
- Mass General Brigham, Boston
U tijeku regrutacijaFaza 1/2
Od 18 godina i više · Oba spola · Ažurirano 23. ruj 2026. · NCT07116616Study of Belantamab Mafodotin With Carfilzomib, Pomalidomide, and Dexamethasone in Relapsed Multiple Myeloma
- Beth Israel Deaconess Medical Center, Boston
U tijeku regrutacijaFaza 2
Od 18 godina i više · Oba spola · Ažurirano 23. ruj 2026. · NCT05789303ELISA in Relapsed/Refractory MM
- Massachusetts General Hospital, Boston
- Beth Israel Deaconess Medical Center, Boston
- Dana Farber Cancer Institute, Boston
U tijeku regrutacijaFaza 2
Od 18 godina i više · Oba spola · Ažurirano 16. ruj 2026. · NCT06832865A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)
- Boston Medical Center, Boston
U tijeku regrutacijaFaza 3
Od 18 godina i više · Oba spola · Ažurirano 15. ruj 2026. · NCT06615479Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma
- Massachusetts General Hospital, Boston
- Dana-Farber Cancer Institute, Boston
U tijeku regrutacijaFaza 2
Od 18 godina i više · Oba spola · Ažurirano 14. ruj 2026. · NCT06297226A Study to Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)
- Dana-Farber Cancer Institute /ID# 271846, Boston
U tijeku regrutacijaFaza 1/2
Od 18 godina i više · Oba spola · Ažurirano 14. ruj 2026. · NCT06953960Elranatamab in R/R Multiple Myeloma
- Massachusetts General Hospital, Boston
- Dana-Farber Cancer Institute, Boston
- Beth-Israel Deaconess Medical Center, Boston
U tijeku regrutacijaFaza 2
Od 18 godina i više · Oba spola · Ažurirano 31. kol 2026. · NCT06138275Study of SIM0500 Alone in Participants With Relapsed or Refractory Multiple Myeloma
- Dana Farber Cancer institution, Boston
U tijeku regrutacijaFaza 1
Od 18 godina i više · Oba spola · Ažurirano 28. kol 2026. · NCT06375044A Study to Evaluate a Novel Gene Therapy in Patients With Relapsed and Refractory Multiple Myeloma
- Massachusetts General Hospital, Boston
U tijeku regrutacijaFaza 1
Od 18 godina i više · Oba spola · Ažurirano 28. kol 2026. · NCT07075185MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)
- Beth Israel Deaconess Medical Center, Boston
- BIDMC Research Pharmacy, Boston
U tijeku regrutacijaFaza 3
Od 18 godina i više · Oba spola · Ažurirano 24. kol 2026. · NCT06152575A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments
- GSK Investigational Site, Boston
U tijeku regrutacijaFaza 1/2
Od 18 godina i više · Oba spola · Ažurirano 19. kol 2026. · NCT05714839AZD0305 as Monotherapy or in Combination With Anticancer Agents in Participants With Multiple Myeloma
- Research Site, Boston
U tijeku regrutacijaFaza 1/2
Od 18 godina i više · Oba spola · Ažurirano 19. kol 2026. · NCT06106945Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial
- Tufts Medical Center, Boston
- Tufts Medical Center Cancer Center Stoneham, Stoneham
U tijeku regrutacijaFaza 3
Od 18 godina i više · Oba spola · Ažurirano 19. kol 2026. · NCT04566328A Trial to Learn if Linvoseltamab is Safe and Works in Adults With Relapsed or Refractory Systemic Light Chain Amyloidosis (AL Amyloidosis)
- Boston Medical Center, Boston
U tijeku regrutacijaFaza 1/2
Od 18 godina i više · Oba spola · Ažurirano 18. kol 2026. · NCT06292780A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma
- Massachusetts General Hospital, Boston
- Dana-Farber Cancer Institute, Boston
U tijeku regrutacijaFaza 1
Od 18 godina i više · Oba spola · Ažurirano 18. kol 2026. · NCT05651932Systemic Anti-Cancer Therapy Dose Modifications for Individuals With Duffy Null Phenotype
- Dana-Farber Cancer Institute, Boston
U tijeku regrutacijaFaza 1
Od 18 godina i više · Oba spola · Ažurirano 17. kol 2026. · NCT07341867AZD0120 in Relapsed/Refractory Multiple Myeloma (DURGA-1)
- Research Site, Boston
- Research Site, Boston
U tijeku regrutacijaFaza 1/2
Od 18 godina i više · Oba spola · Ažurirano 17. kol 2026. · NCT05850234Immuno-PRISM (PRecision Intervention Smoldering Myeloma)
- Dana Farber Cancer Institute, Boston
U tijeku regrutacijaFaza 2
Od 18 godina i više · Oba spola · Ažurirano 16. srp 2026. · NCT05469893A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of Arlocabtagene Autoleucel (BMS-986393) in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma
- Beth Israel Deaconess Medical Center, Boston
- Dana-Farber Cancer Institute, Boston
U tijeku regrutacijaFaza 1
Od 18 godina i više · Oba spola · Ažurirano 16. srp 2026. · NCT06121843Selinexor and Backbone Treatments of Multiple Myeloma Patients
- Dana Farber Cancer Institute, Boston
U tijeku regrutacijaFaza 1/2
Od 18 godina i više · Oba spola · Ažurirano 15. srp 2026. · NCT02343042A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Participants With Multiple Myeloma That is Resistant to Current Standard of Care Treatments
- Dana Farber/Harvard Cancer Center, Boston
U tijeku regrutacijaFaza 1
Od 18 godina i više · Oba spola · Ažurirano 8. srp 2026. · NCT05137054Integrated Cancer Repository for Cancer Research
- Holyoke Medical Center, Holyoke
U tijeku regrutacijaOpažajna studijaZdravi dobrovoljci dobrodošli
Od 19 do 110 godina · Oba spola · Ažurirano 29. lip 2026. · NCT02012699Low-Dose Radiotherapy in Treating Painful Bone Metastases in Patients With Multiple Myeloma
- Dana-Farber Cancer Institute, Boston
U tijeku regrutacija
Od 18 godina i više · Oba spola · Ažurirano 5. lip 2026. · NCT03858205Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation
- Tufts Medical Center, Boston
- Beth Israel Deaconess Medical Center, Boston
U tijeku regrutacijaFaza 3
Od 18 godina i više · Oba spola · Ažurirano 4. lip 2026. · NCT05243797Study to Assess Safety and Tolerability of OPN-6602 in Subjects With Relapsed and/or Refractory Multiple Myeloma
- Dana Farber Cancer Institute, Boston
U tijeku regrutacijaFaza 1
Od 18 godina i više · Oba spola · Ažurirano 19. svi 2026. · NCT06433947DC/MM Fusion Vaccine With BCMA CAR-T in R/R MM
- Beth Israel Deaconess Medical Center, Boston
U tijeku regrutacijaFaza 1
Od 18 godina i više · Oba spola · Ažurirano 8. svi 2026. · NCT07377435A Phase 1 Study of Vaccination With Dendritic Cell (DC)/Multiple Myeloma (MM) Fusions in Combination With Elranatamab in Relapsed or Refractory Multiple Myeloma
- Beth Israel Deaconess Medical Center, Boston
- Dana-Farber Cancer Institute, Boston
U tijeku regrutacijaFaza 1
Od 18 godina i više · Oba spola · Ažurirano 7. svi 2026. · NCT06799026Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.
- Dana Farber Cancer Institute, Boston
U tijeku regrutacijaFaza 1
Od 13 godina i više · Oba spola · Ažurirano 5. svi 2026. · NCT04771572A Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM)
- GSK Investigational Site, Worcester
U tijeku regrutacijaFaza 3
Od 18 godina i više · Oba spola · Ažurirano 22. tra 2026. · NCT06679101Defining the Role of Palliative carE for Patients With Hematologic Malignancies Undergoing Adoptive CEllular Therapy
- Massachusetts General Hospital Cancer Center, Boston
U tijeku regrutacija
Od 18 godina i više · Oba spola · Ažurirano 21. tra 2026. · NCT05646576Mezigdomide and Talquetamab in Relapsed and Refractory Multiple Myeloma
- Massachusetts General Hospital, Boston
- Beth Israel Deaconess Medical Center, Boston
- Dana-Farber Cancer Institute, Boston
U tijeku regrutacijaFaza 1
Od 18 godina i više · Oba spola · Ažurirano 13. tra 2026. · NCT07032714Study of ISB 2001 in Relapsed/Refractory Multiple Myeloma (TRIgnite-1)
- Beth Israel Deaconess Medical Center, Boston
U tijeku regrutacijaFaza 1
Od 18 godina i više · Oba spola · Ažurirano 1. tra 2026. · NCT05862012A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
- Massachusetts General Hospital, Boston
U tijeku regrutacijaFaza 1/2
Od 12 godina i više · Oba spola · Ažurirano 24. ožu 2026. · NCT04988555A Study to Assess BMS-986453 in Participants With Relapsed and/or Refractory Multiple Myeloma
- Dana-Farber Cancer Institute, Boston
U tijeku regrutacijaFaza 1
Od 18 godina i više · Oba spola · Ažurirano 18. ožu 2026. · NCT06153251Prehabilitation Exercise Training in Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation
- Dana Farber Cancer Institute, Boston
- Dana-Farber Cancer Institute, Boston
U tijeku regrutacija
Od 18 godina i više · Oba spola · Ažurirano 22. sij 2026. · NCT05706766Iz ClinicalTrials.gov, podaci preuzeti 5. lis 2026.. Svaka studija ima svoje uvjete prihoda; tim studije odlučuje tko se može priključiti.